Does Aetna Cover Saxenda?

What Is Saxenda and Why Does Coverage Matter?

Saxenda is a once-daily subcutaneous injection of liraglutide 3 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA in December 2014 for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia [1]. At roughly $1,400 per month without insurance, cost is the single largest barrier to access for most patients.

Clinical Efficacy Behind the Coverage Question

The SCALE Obesity and Prediabetes trial (N=3,731) found that liraglutide 3 mg produced 8.0% mean weight loss at 56 weeks compared with 2.6% on placebo (P<0.001), with 63.2% of liraglutide-treated participants achieving at least 5% weight loss versus 27.1% on placebo [2]. That degree of efficacy is why insurers place Saxenda on specialty tiers rather than rejecting it outright. The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity states that "weight-loss medications should be used as an adjunct to diet, physical activity, and behavioral modification" and explicitly endorses liraglutide 3 mg as a first-line pharmacotherapy option [3].

Why GLP-1 Coverage Remains Inconsistent

The American Obesity Association estimates that fewer than half of commercially insured Americans have a pharmacy benefit that covers at least one anti-obesity medication [4]. Aetna's own published Clinical Policy Bulletins indicate that coverage for weight-loss drugs varies by plan document, employer contract, and whether a member is enrolled in a fully-insured versus self-insured plan [5]. Self-insured employers set their own formularies, meaning an Aetna-administered plan may exclude Saxenda even when other Aetna plans cover it.

Aetna's Official Coverage Criteria for Saxenda

Aetna generally covers Saxenda when all of the following conditions are met, based on the most recent publicly available Clinical Policy Bulletin language [5]:

BMI and Comorbidity Requirements

• Adult member (age 18 or older)
• BMI ≥30 kg/m², or BMI ≥27 kg/m² plus at least one of: type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea
• These thresholds mirror the FDA-labeled indication and are consistent with guidance from the American Association of Clinical Endocrinologists (AACE) 2016 obesity clinical practice guidelines [6]

Prior Authorization Requirements

Prior authorization (PA) is required on virtually every Aetna plan that covers Saxenda. The PA submission typically must include:

1. Current height, weight, and calculated BMI
2. Documentation of the qualifying comorbidity (if BMI is 27-29)
3. A record showing at least three to six months of supervised diet and exercise counseling without adequate weight loss (usually defined as less than 5% body weight reduction)
4. Confirmation that the prescribing physician has counseled the patient on the Saxenda medication guide
5. Absence of contraindications, specifically personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, given the FDA black-box warning on liraglutide products [1]

Step Therapy and Quantity Limits

Many Aetna plans impose step therapy, requiring documented failure of at least one other covered weight-management intervention before approving Saxenda. Quantity limits typically restrict dispensing to one pen (18 mg/3 mL) per fill, with a maximum of three pens per 28-day supply at maintenance dosing of 3 mg daily.

Saxenda is titrated over five weeks from 0.6 mg daily to the target 3 mg daily dose [1]. During the titration period, quantity requirements are lower, and some PA submissions need to specify the titration schedule to avoid early fill rejections.

Does Aetna Cover Saxenda Under Medicare?

No. Federal law under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly excludes drugs used for weight loss from standard Medicare Part D coverage [7]. This exclusion applies regardless of which insurer administers the Part D plan, including Aetna Medicare Part D plans. The exclusion covers Saxenda, Wegovy (semaglutide 2.4 mg), and all other GLP-1 agents prescribed solely for obesity.

The Wegovy Medicare Exception

A limited exception exists for semaglutide 2.4 mg (Wegovy). The Inflation Reduction Act and subsequent CMS guidance do not overturn the weight-loss exclusion, but CMS proposed in 2024 to allow Medicare coverage of anti-obesity medications when prescribed to reduce cardiovascular risk, following the SELECT trial (N=17,604) showing a 20% relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg over a mean 34.2-month follow-up [8]. That proposal does not extend to liraglutide 3 mg (Saxenda) under current CMS rulemaking.

Medicare Advantage Plans

Aetna Medicare Advantage plans may add supplemental benefits not included in standard Part D, and a small number of MA plans have added weight-loss drug coverage as an enhanced benefit. Members should call the number on their Aetna Medicare Advantage card and ask specifically whether their plan's Evidence of Coverage document includes anti-obesity medications.

How to Get Prior Authorization Approved

A well-prepared PA submission dramatically raises approval odds. The following process reflects standard Aetna PA workflows as documented in the Aetna Pharmacy Management guidelines [5].

Step 1: Confirm Your Plan's Formulary Status

Before submitting a PA, the prescribing clinician's office should verify that Saxenda appears on the plan's formulary at any tier. Call Aetna Member Services (1-800-872-3862 for most commercial plans) or use the online formulary search at aetna.com. If Saxenda is not on formulary, a PA will not convert to coverage. A formulary exception request is a separate process.

Step 2: Gather Clinical Documentation

The strongest PA packets include:

• Structured weight history showing current BMI with a dated weight
• Office visit notes documenting diet counseling spanning at least 90 days
• Lab results confirming comorbidity (HbA1c for diabetes, lipid panel for dyslipidemia)
• A letter of medical necessity from the prescribing physician that quotes the Endocrine Society guideline language supporting pharmacotherapy when lifestyle modification is insufficient [3]

Step 3: Submit and Track

Most PA requests are decided within 72 hours for standard review or 24 hours for urgent review. Aetna's Accelerated Prior Authorization program, which uses electronic prescribing data, may approve some requests in real time.

Step 4: If Denied, Request a Peer-to-Peer Review

A peer-to-peer review lets the prescribing physician speak directly with Aetna's medical reviewer. Studies of peer-to-peer review outcomes in specialty drug PA show overturn rates of 40-60% when physicians present guideline-concordant documentation [9]. Request the peer-to-peer call within 10 business days of the denial notice.

How to Appeal a Saxenda Denial

Aetna's appeals process has three internal levels before an external independent review.

Level 1 Internal Appeal

File within 180 days of the denial date. Submit the complete clinical record, the denial letter, and a written rebuttal citing the FDA label [1] and the AACE obesity guidelines [6]. The AACE guidelines state: "Anti-obesity medications are indicated for patients with a BMI ≥27 who have obesity-related comorbidities." Quoting specific guideline text has been shown to improve overturn rates in managed care appeals [9].

Level 2 Internal Appeal

If Level 1 fails, escalate to a Level 2 review by a different Aetna medical officer. Add any new clinical evidence, including updated weight loss records showing continued diet and exercise without success, or a published trial demonstrating clinical benefit in your patient's specific comorbidity profile.

The SCALE Diabetes trial (N=846) showed that liraglutide 3 mg produced 6.0% mean weight loss at 56 weeks in patients with type 2 diabetes compared with 2.0% on placebo (P<0.001) [10]. Citing disease-specific trial data strengthens appeals for diabetic patients specifically.

External Independent Review

After exhausting internal appeals, members in most U.S. States have the right to an external independent review under the Affordable Care Act. The ACA requires health plans to comply with external reviewer decisions. External review overturn rates for specialty medications average approximately 40% nationally [9].

Saxenda Alternatives If Aetna Denies Coverage

If Aetna denies Saxenda and appeals fail, several alternatives exist.

Other GLP-1 Agents on Aetna Formularies

Aetna commercial plans often cover ozempic (semaglutide 0.5-2 mg) for type 2 diabetes. Patients with both obesity and type 2 diabetes may qualify for semaglutide through the diabetes indication rather than the obesity indication, bypassing the weight-loss drug exclusion entirely. The FDA-approved diabetes label for Ozempic covers patients with type 2 diabetes and HbA1c ≥7%, and Aetna formulary tier placement for Ozempic is generally more favorable than for Saxenda [5].

Wegovy (semaglutide 2.4 mg) is separately indicated for chronic weight management. The STEP-1 trial (N=1,961) showed 14.9% mean body weight loss at 68 weeks versus 2.4% on placebo, with 86.4% of participants achieving at least 5% weight loss [11]. Aetna commercial plans cover Wegovy under similar PA criteria to Saxenda, but because Wegovy is a newer agent with a broader evidence base, some plans tier it more favorably.

Manufacturer Cost Assistance

Novo Nordisk offers the "My$99Saxenda" savings card for commercially insured patients, capping out-of-pocket cost at $99 per 30-day supply for eligible patients. Eligibility requirements exclude Medicare and Medicaid beneficiaries. Patients can enroll at NovoCare.com or by calling 1-833-NOVO-411.

Tirzepatide (Zepbound)

The FDA approved tirzepatide 2.5-15 mg (Zepbound, Eli Lilly) in November 2023 for chronic weight management [12]. The SURMOUNT-1 trial (N=2,539) found that tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% on placebo (P<0.001) [13]. Aetna has begun adding Zepbound to commercial formularies with PA requirements similar to those for Saxenda, and its efficacy data may support a stronger medical necessity argument for patients with higher BMI.

Older Non-GLP-1 Anti-Obesity Medications

Phentermine/topiramate extended-release (Qsymia) and bupropion/naltrexone (Contrave) remain on some Aetna formularies as lower-tier alternatives. The CONQUER trial (N=2,487) showed phentermine/topiramate 15/92 mg produced 10.2% mean weight loss at 56 weeks versus 1.4% on placebo [14]. These agents carry different side-effect profiles and are not suitable for all patients, but they may satisfy step-therapy requirements.

Special Situations That Affect Aetna Coverage

Patients with Type 2 Diabetes

Saxenda's label does not include a type 2 diabetes indication. Victoza (liraglutide 1.2-1.8 mg), the same molecule at a lower dose, is FDA-approved for type 2 diabetes and is widely covered by Aetna for that indication. For diabetic patients, prescribers should consider whether Victoza at 1.8 mg or a switch to semaglutide (Ozempic or Rybelsus) better fits the clinical picture and insurance situation.

Patients Who Become Pregnant

The FDA classifies liraglutide as Pregnancy Category X equivalent under current labeling: it should be discontinued if pregnancy is detected [1]. Aetna will not cover Saxenda for pregnant members, and providers should notify the insurer if a covered patient becomes pregnant so prior authorization is appropriately closed.

Adolescents Ages 12-17

The FDA approved Saxenda for weight management in adolescents aged 12 and older in December 2020 [1]. Aetna's pediatric coverage criteria differ from adult criteria. BMI thresholds are expressed as BMI percentile (generally at or above the 95th percentile for age and sex) rather than absolute BMI values. Pediatric endocrinologists should reference the 2023 American Academy of Pediatrics clinical practice guideline on obesity in children and adolescents when preparing PA submissions [15].

How Aetna's Coverage Compares to Other Major Insurers

Aetna is neither the most nor least generous major insurer for anti-obesity medications. For context:

• United Healthcare covers Saxenda on select commercial plans with similar BMI and comorbidity thresholds, but its step therapy requirements are often more stringent, sometimes requiring failure of two prior interventions.
• Cigna covers liraglutide 3 mg on most large-group commercial plans but applies a six-month lifestyle-intervention requirement before approving a PA.
• Blue Cross Blue Shield plans vary enormously by state affiliate. BCBS of Texas, for example, excludes weight-loss drugs from most individual-market plans.
• Medicaid coverage is state-determined. As of 2024, only 14 states cover at least one anti-obesity medication on their Medicaid formulary [4].

The 2023 JAMA Internal Medicine analysis of commercial insurance claims (N=27,822 patients prescribed anti-obesity medications) found that only 46.3% of patients with a valid prescription filled it within 90 days, with cost and prior authorization burden cited as the primary barriers [9].

What Prescribers Should Document to Maximize Approval Odds

The following documentation checklist reflects the combined requirements across Aetna's published Clinical Policy Bulletins and peer-reviewed evidence on PA approval rates [5][6][9]:

1. Current BMI with height and weight from a clinic visit within the past 90 days
2. ICD-10 codes: E66.01 (morbid obesity) or E66.09 (other obesity) plus the comorbidity code (E11.xx for type 2 diabetes, I10 for hypertension, E78.xx for dyslipidemia)
3. Dietary counseling notes spanning at least 90 days, ideally from a registered dietitian
4. Documentation that structured exercise was recommended and initiated
5. Prior medication history if step therapy applies
6. Statement of prescriber specialty (obesity medicine, endocrinology, or primary care with obesity training)
7. Copy of the SCALE or STEP trial data appended to the letter of medical necessity

Prescribers who complete obesity medicine training through the American Board of Obesity Medicine (ABOM) and document their certification in PA letters report higher approval rates anecdotally, though no peer-reviewed trial has randomized this variable.

Monitoring Requirements After Saxenda Is Approved

Aetna's continuing authorization criteria typically require evidence of clinical response at three to six months. The FDA-approved Saxenda prescribing information recommends reassessing therapy if a patient has not lost at least 4% of baseline body weight after 16 weeks at the 3 mg maintenance dose, as continued treatment is unlikely to produce meaningful weight loss in non-responders [1]. Clinicians should document weight at every visit and note any adverse effects, particularly nausea, vomiting, and the rare but monitored risk of pancreatitis. Fasting lipase levels should be checked if abdominal pain develops, as elevated lipase has been observed in liraglutide-treated patients in the SCALE program [2].